StataDx

The company seeks to help patients and physicians monitor brain health in a way comparable to blood sugar monitoring.

Sabaté del Río, J., Henry, O.Y.F., Jolly, P., Ingber, D.E. An antifouling coating that enables affinity-based electrochemical biosensing in complex biological fluids. Nature Nanotechnology 14, 1143–1149 (2019).

The startup will develop and commercialize cost-effective, highly sensitive and specific point-of-care diagnostics, applying a novel electrochemical sensor platform created at the Wyss Institute

The company envisions making brain health checks as accessible as blood sugar checks.

The company offers biomarker panels for use in clinical trials at scale.

Sidhant Jena leads **StataDX**, developing a **point-of-care neurological testing platform** to simplify brain health monitoring. His background includes scaling companies from concept to **FDA approval**. Jena is part of the **Alzheimer’s & Brain Health Moonshot Community**, focusing on accessible diagnostic solutions.

Jul 2025StartUp HealthNews article

StataDx secures **$1.79 million in Seed funding** to develop the first point-of-care diagnostics platform for neurology. The Boston-based startup focuses on enabling rapid, accessible neurological assessments. The round closed on **March 21, 2024**, marking a key milestone in its growth.

Mar 2024app.fundz.netNews article

StataDX licenses Harvard Wyss Institute’s **eRapid multiplexed biosensor technology** to create point-of-care diagnostics for neurological, cardiovascular, and renal diseases. The electrochemical sensor platform enables highly sensitive, cost-effective tests. The startup plans to develop and commercialize these diagnostics for clinical use.

Jun 2022Wyss InstituteNews article